AURINIA PHARMACEUTICALS INC
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2012-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
26
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials
Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Aurinia Pharmaceuticals Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05962788
- Locations
- 🇺🇸
UNC-Chapel Hill, Chapel Hill, North Carolina, United States
🇨🇴Clinica de la Costa S.A.S, Barranquilla, Atlantico, Colombia
🇯🇵Yokohama City University Hospital, Yokohama, Kanagawa, Japan
A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Aurinia Pharmaceuticals Inc.
- Target Recruit Count
- 229
- Registration Number
- NCT05337124
- Locations
- 🇺🇸
Site 00-05, South Gate, California, United States
Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Aurinia Pharmaceuticals Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05306379
- Locations
- 🇺🇸
Labcorp Clinical Research Unit, Dallas, Texas, United States
Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis
- Conditions
- Adolescent Lupus NephritisPediatric Lupus Nephritis
- Interventions
- Drug: Placebo Oral Capsule
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Aurinia Pharmaceuticals Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05288855
- Locations
- 🇺🇸
Nemours Children's Hospital, Orlando, Orlando, Florida, United States
🇨🇴Clinica de la Costa S.A.S, Barranquilla, Atlantico, Colombia
🇯🇵Yokohama City University Hospital, Yokohama, Kanagawa, Japan
Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome
- Conditions
- Keratoconjunctivitis SiccaDry Eye Syndrome
- Interventions
- Drug: 0.10% VOSDrug: 0.05% Voclosporin Ophthalmic Solution (VOS)Drug: 0.20% VOSDrug: Vehicle Ophthalmic Solution
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Aurinia Pharmaceuticals Inc.
- Target Recruit Count
- 508
- Registration Number
- NCT04147650
- Locations
- 🇺🇸
Aurinia Investigative Center, Nashville, Tennessee, United States
- Prev
- 1
- 2
- 3
- 4
- Next